Key result
Postmenopausal hormone-replacement therapy shows conflicting observational links with cardiovascular disease, spanning half to double risk.
Answers are grounded in this paper and cite their sources.
Eighteen years ago, the Journal published two observational studies1,2 of the relations between postmenopausal hormone-replacement therapy and cardiovascular diseases. One found that women who used such therapy had about half the risk that nonusers had; the other found that they had almost twice the risk. In each study, the relative risk was statistically different from a relative risk of 1.0, or no effect. These results seemed to be in serious conflict, although each study taken alone looked sound. In an accompanying editorial,3 I noted differences in the drugs used, the groups of patients studied, the outcomes ascertained, and other . . .
No takes yet. Share an insight, caveat, or question.
John C. Bailar (2003) conducted an editorial in Cardiovascular diseases in postmenopausal women. Postmenopausal hormone-replacement therapy vs. Nonusers was evaluated on Cardiovascular diseases. Postmenopausal hormone-replacement therapy showed conflicting associations with cardiovascular disease across prior observational studies, ranging from roughly half to almost twice the risk.
Synapse has enriched 10 related papers. Consider them for comparative context: